![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 37, 29100-29106, September 15, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, March 13, 2000, and in revised form, June 22, 2000
The Rad51 protein in eukaryotic cells is a
structural and functional homolog of Escherichia coli RecA
with a role in DNA repair and genetic recombination. Several proteins
showing sequence similarity to Rad51 have previously been identified in
both yeast and human cells. In Saccharomyces cerevisiae,
two of these proteins, Rad55p and Rad57p, form a heterodimer that can
stimulate Rad51-mediated DNA strand exchange. Here, we report the
purification of one of the representatives of the RAD51 family in human
cells. We demonstrate that the purified RAD51L3 protein possesses
single-stranded DNA binding activity and DNA-stimulated ATPase
activity, consistent with the presence of "Walker box" motifs in
the deduced RAD51L3 sequence. We have identified a protein complex in
human cells containing RAD51L3 and a second RAD51 family member, XRCC2.
By using purified proteins, we demonstrate that the interaction between RAD51L3 and XRCC2 is direct. Given the requirements for XRCC2 in
genetic recombination and protection against DNA-damaging agents, we
suggest that the complex of RAD51L3 and XRCC2 is likely to be important
for these functions in human cells.
Genetic recombination is an essential process in eukaryotic cells
with roles in both meiotic and mitotic cells. During meiosis, genetic
recombination is required both for the generation of genetic diversity
and for ensuring that segregation of homologous chromosomes occurs
faithfully at meiosis I. In the mitotic cell cycle, the major role for
recombination is probably in the elimination of DNA damage, including
repair of DNA double strand breaks and cross-links (1).
In bacteria, the process of genetic recombination depends upon the RecA
protein, which forms nucleoprotein filaments on DNA and promotes DNA
strand exchange between homologous sequences (1, 2). Structural and
functional homologs of RecA have been isolated from several other
organisms, including yeasts and mammalian cells, where the genes have
been designated RAD51 (3-8). Strains of Saccharomyces
cerevisiae carrying a deletion of the RAD51 gene are
viable but are highly sensitive to ionizing radiation and are defective
in meiosis (7). The S. cerevisiae Rad51 protein has been
purified and shown to form nucleoprotein filaments and promote DNA
strand exchange, albeit far less efficiently than does RecA (6, 9, 10).
In contrast to yeast, the equivalent gene in mammalian cells
(RAD51) has been shown to be essential for embryonic
development, as determined by analysis of mice homozygous for a
targeted deletion of the RAD51 gene (11, 12).
Efficient genetic recombination in S. cerevisiae requires
several genes other than RAD51, including RAD52,
RAD54, RAD55, RAD57, and
RAD59. These genes belong to the same epistasis group (the RAD52 group) and are therefore considered to operate in the
same biochemical pathway (1). This supposition has been validated through biochemical analyses, which have shown, for example, that Rad51p makes specific interactions with Rad52p, Rad54p, and Rad55p (13,
14). Functional homologs of Rad52p and Rad54p have been identified in
mammalian cells, and their biochemical properties have been partially
characterized (15-18). Rad55p and Rad57p show some primary sequence
similarity to RecA but do not appear to perform the same biochemical
function(s) as Rad51p (13, 19). Instead, Rad55p and Rad57p form a
heterodimer that is thought to act as a Rad51 accessory factor greatly
stimulating the efficiency with which Rad51 catalyzes DNA strand
exchange (20). Consistent with this important role in genetic
recombination, rad55 and rad57 mutants have a
phenotype similar to that of rad51 mutants, including extreme sensitivity to ionizing radiation (1).
To date, no obvious RAD55 and RAD57 orthologs
have been identified in human cells. Nevertheless, several genes have
been isolated from rodent and human cells that show a limited degree of
sequence similarity to RAD51. These genes were identified
either through data base searching (RAD51L1,
RAD51L2, and RAD51L3, also known as RAD51B,
RAD51C, and RAD51D, respectively) or through functional complementation of x-ray-sensitive rodent cell mutants
(XRCC2 and XRCC3) (21-28). Although the
functional roles of the RAD51L1/L2/L3 proteins can only be surmised at
this stage, there is good evidence that the XRCC2 and XRCC3 proteins
participate in genetic recombination processes. The mutants of Chinese
hamster ovary (XRCC3) or V79 cells (XRCC2)
defective in these proteins show mild sensitivity to ionizing radiation
but extreme sensitivity to DNA cross-linking agents (29, 30). Both
mutants also show an elevated incidence of spontaneous and
radiation-induced chromosomal aberrations (30-32). Moreover, the
XRCC2 mutant cell line (irs1) displays a 100-fold decrease
in the frequency of homologous recombinational repair of DNA double
strand breaks (33). Evidence that XRCC3 also operates in the RAD51
pathway comes from the finding that the characteristic nuclear focal
pattern of localization for RAD51 is disrupted in XRCC3
mutants (34).
Although the sequence similarities of the human RAD51-like proteins to
their yeast counterparts are limited, multiple protein sequence
alignments of eukaryotic RAD51 family members suggest that RAD51L3 may
be closer in structure to the yeast Rad57p than to the other family
members (35). Similarly, the closest human RAD51-like protein to Rad55p
is XRCC2. The biochemical functions of these human RAD51-like proteins
have not been explored, and therefore as a first step in understanding
these functions, we have purified both RAD51L3 and XRCC2 following
expression in Escherichia coli. We show that RAD51L3 is a
DNA-stimulated ATPase that binds specifically to single-stranded DNA.
We present evidence that RAD51L3 forms a complex with XRCC2 in human
cells and that this interaction is direct.
Construction of Plasmids--
cDNA for RAD51L3
was amplified from a human testis cDNA library
(CLONTECH; HL1142q) using the polymerase chain
reaction. The complete open reading frame
(ORF)1 for RAD51L3 was
further amplified with primers that incorporate a 5' EcoRI
(5'-AGAGAGGAATTCCTAACCATGGGCGTGCTCAGGGTC) and a 3' NotI (5'-AGAGAGGCGGCCGCTTCATGTCTGATCACCCTG)
restriction site (underlined in each case). The amplified DNA was
cloned into pET30a (Novagen) and pGEX4T-1 (Amersham Pharmacia Biotech)
to create pJB3.1 and pJB3.2, respectively. In sequencing the human
RAD51L3 gene from several different sources, we found
that a polymorphism occurs at nucleotide position 613 (G or A),
predicting an amino acid variation at position 165 of the protein (Arg
or Gln). This sequence variation has been noted in different nucleotide
data base entries (compare Y15572 with GenBankTM
ABO13341). The cDNA used for these studies (23) carried the nucleotide 613A. The ORF for XRCC2 was amplified with primers that
incorporate a 5' BamHI
(5'-AGAGAGGGATCCATGTGTAGTGCCTTCCATAGG) and a 3'
EcoRI (5'-AGAGAGGAATTCTCAACAAAATTCAACCCCACT)
restriction site (underlined in each case), before cloning into
pGEX4T-1 or pET30a to generate pJB1.1 and pJB1.2. The final constructs
pJB3.1, pJB3.2, pJB1.1, and pJB1.2 were sequenced (ABI Dye Terminator Cycle Sequencing, Perkin-Elmer) to confirm that no errors were incorporated during the amplification process.
Cell Lines--
The SV40-transformed human fibroblast cell line
WI-38/VA-13, which was obtained from the ATCC, was used as a
representative "normal" human cell line. HeLa S3 (human cervical
carcinoma) cells were also used for pull-down and gel filtration
experiments. WI-38/VA-13 cells were cultured in Expression of Recombinant His-RAD51L3, His-XRCC2, RAD51L3-GST,
and XRCC2-GST--
E. coli strain BL21( Purification of Recombinant His-RAD51L3 and His-XRCC2--
All
procedures were carried out at 4 °C unless stated otherwise. Cells
were thawed, resuspended in lysis buffer (final concentration 25 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.2% Triton
X-100, 10 mM imidazole, and "Complete EDTA-free protease
inhibitor tablets" (Roche Molecular Biochemicals)), and incubated on
ice for 30 min. PMSF was added to a final concentration of 1 mM immediately prior to lysis by sonication (4 × 15 s with cooling on ice). The lysate was cleared by
centrifugation at 39,000 rpm for 25 min in a Beckman 70Ti rotor. The
supernatant was then subjected to nickel chelate affinity
chromatography. After charging a 1.7-ml Poros MC20 column (Applied
Biosystems) with 50 ml of 100 mM NiSO4, the
column was saturated with 5 bed volumes of 1500 mM
imidazole in 25 mM Tris-HCl, pH 7.5, 500 mM
NaCl and then equilibrated with 5 bed volumes of 10 mM
imidazole in the same buffer. The supernatant was loaded onto the
column using a BioCAD workstation (Applied Biosystems), and the column
was washed with 25 bed volumes of the same buffer containing 100 mM imidazole. Elution was performed with an imidazole gradient of 100-1500 mM in the same buffer applied over 8 bed volumes. Fractions of 1 ml were collected, and those containing RAD51L3 or XRCC2, as determined by spectrophotometric monitoring (A280) and SDS-PAGE, were dialyzed at 4 °C
for at least 4 h against buffer containing 25 mM
Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM DTT. RAD51L3 was further purified by heparin affinity
chromatography. Disposable columns (Bio-Rad) containing 1-ml bed volume
of immobilized heparin-agarose resin (Pierce) were equilibrated with 10 bed volumes of binding buffer (25 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM DTT).
Dialyzed RAD51L3 eluate was loaded onto the column; the column was
washed with 15 bed volumes of the same buffer containing 250 mM NaCl, and proteins were eluted with the same buffer
containing 600 mM NaCl. Fractions of 0.5 ml were collected,
and those containing recombinant RAD51L3 (rRAD51L3), as determined by
SDS-PAGE, were dialyzed for 16 h against buffer containing 25 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol. Protein
samples were stored in aliquots at Purification of Recombinant RAD51L3-GST and XRCC2-GST Fusion
Proteins--
Pellets were thawed and resuspended in buffer containing
25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and
complete protease inhibitor tablets (Roche Molecular Biochemicals). Cells were lysed and centrifuged as described above for RAD51L3. The
supernatant was loaded onto Bio-Rad disposable columns (at 4 °C)
containing 1-ml bed volume of glutathione-agarose resin (Sigma),
previously washed with 10 bed volumes of buffer containing 25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM EDTA, 1 mM DTT. The columns were
subsequently washed with a further 10 bed volumes of the same buffer
before the resin was either boiled in SDS-PAGE loading buffer or used
immediately in "pull-down" experiments (see below).
Antibodies--
IHIC42 and IHIC48 were generated by immunizing
New Zealand White rabbits with 6 × 100-µg subcutaneous
injections of either an inclusion body preparation of His-tagged
rRAD51L3 protein (representing amino acids 120-328) or denatured
His-tagged rXRCC2 (full ORF). The sera were affinity purified against
rRAD51L3 protein or rXRCC2, respectively. For this, whole cell lysates
containing several milligrams of overexpressed recombinant protein were
subjected to SDS-PAGE and transferred to nitrocellulose membrane
(Hybond C-extra, Amersham Pharmacia Biotech). The membranes were
stained with Ponceau S and the band corresponding to rRAD51L3 or rXRCC2 cut out. Filters were blocked in PBSA containing 5% low fat milk powder, 0.1% Tween 20 for 30 min, before overnight incubation at
4 °C with 2 ml of serum. After 4 × 10-min washes in PBSA plus 0.1% Tween 20, anti-RAD51L3 or anti-XRCC2 antibodies were eluted in
500 µl of 0.1 M glycine HCl, pH 2.5, for 5 min at
20 °C, and the sample was neutralized by the addition of 335 µl of
1 M Tris-HCl, pH 8.0.
ATPase Assays--
ATPase activity was determined by the release
of 32Pi from [ DNA Binding Assays--
50-nucleotide single-stranded
oligonucleotide, X12-1
(5'-GACGCTGCCGAATTCTGGCTTGCTAGGACATGTTTGCCCACGTTGACCC), or
52-nucleotide oligonucleotide BL3
(5'-AAAATGAGAAAATTCGACCTATCCTTGCGCAGCTCGAGAAGCTCTTACTTTG) were
5'-end-labeled with [32P]dATP using standard protocols.
BL3 was annealed to BL4
(5'-CAAAGTAAGAGCTTCTCGAGCTGCGCAAGGATAGGTCGAATTTTCTCATTTT) to
create blunt-ended double-stranded DNA. Protein and DNA were incubated
in 25 mM Tris-HCl, pH 7.5, 100 µg/ml BSA, 1 mM DTT, 1 mM EDTA and 2.5 mM
MgCl2 at room temperature for 15 min. Protein-DNA complexes
were visualized by autoradiography after separation using 5% neutral
PAGE run at 4 °C.
Yeast Two-hybrid Analysis--
Full-length cDNAs of human
RAD51L3 and XRCC2 were isolated from previously
described sources (23, 27) using the polymerase chain reaction with
Taq (Advanced Biotechnologies) and Pfu
(Stratagene) polymerases in a ratio of 1:8. Polymerase chain reaction
primers were designed with restriction sites to aid cloning in frame
into either bait (pHybLex/Zeo) or prey (pYESTrp2) vectors (Invitrogen); constructs were transformed into E. coli, amplified, and
checked by sequencing. Co-transformations into the yeast L40 strain
were carried out according to the Invitrogen Hybrid Hunter (version B)
protocol. Positive (pHybLex/Zeo-Fos, pYESTrp-Jun) and negative (pHybLex/Zeo-Lamin) controls were used as supplied. Interactions were identified using the Whole Cell and Nuclear Extracts--
Whole cell extracts for
Western blotting were prepared by washing cells in PBSA and then
boiling in protein loading buffer as described above. Nuclear extracts
were prepared from exponentially growing HeLa S3 or WI-38/VA-13 cells.
Approximately 2 × 108 cells were washed in PBSA, and
the pellet was lysed in 5 ml of buffer (10 mM Tris-HCl, pH
7.5, 1.5 mM MgCl2, 10 mM NaCl, 1%
Nonidet P-40, 1 mM DTT), supplemented with protease and
phosphatase inhibitors (1 mM NaF, 1 mM
Western Blotting--
Samples were separated on 12%
SDS-polyacrylamide gels and transferred to nitrocellulose membrane
(Hybond C-extra, Amersham Pharmacia Biotech) using a TE 70 semi-dry
transfer unit (Amersham Pharmacia Biotech). rRAD51L3 and rXRCC2 were
detected either by a mouse monoclonal anti-histidine tag antibody
(Sigma, anti-polyhistidine) or by the IHIC42 and IHIC48 polyclonal
antibodies described above. RAD51L3 was detected in cell extracts by
IHIC42 used at a dilution of 1:1000 (crude serum) or 1:200 when
affinity purified. Affinity purified IHIC48 was used at a dilution of
1:1000. Anti-mouse or anti-rabbit IgG/horseradish peroxidase conjugates
(Sigma) were used as secondary antibody at a dilution of 1:3000 and
1:5000, respectively. Immunoreactive proteins were visualized using ECL reagents (Amersham Pharmacia Biotech) following the manufacturer's instructions.
RAD51L3-GST and XRCC2-GST Pull-downs--
RAD51L3-GST or
XRCC2-GST were bound to glutathione-agarose columns as described above
(typical bed volume 0.5 ml). Purified recombinant protein or nuclear
extracts, as described, were loaded onto the column and washed with 15 ml of TKM/buffer D (ratio 1:2). The column matrix was boiled in protein
sample loading buffer and separated by SDS-PAGE before Western blotting.
Far Western Analysis--
Typically 0.2-0.5 µg of each
polypeptide was subjected to SDS-PAGE and transferred to Hybond C-extra
nitrocellulose membranes (Amersham Pharmacia Biotech) using a TE 70 semi-dry transfer unit (Amersham Pharmacia Biotech). All subsequent
steps were performed at 4 °C. Filters were immersed twice in
denaturation buffer (6 M guanidine HCl in PBSA) for 10 min
and then incubated 6 times for 10 min in denaturation buffer diluted
serially 1:2 with PBSA supplemented with 1 mM DTT. Filters
were then blocked in PBSA containing 10% powdered milk, 0.1% Tween 20 for 30 min before being incubated with rRAD51L3 in PBSA supplemented
with 0.25% milk, 0.1% Tween 20, 1 mM DTT, and 1 mM PMSF for 60 min. Filters were washed 4 times for 10 min
in PBSA containing 0.25% powdered milk, 0.1% Tween 20. The second
wash contained 0.00001% glutaraldehyde. Conventional Western analysis,
as described above, was then performed to detect the presence of
rRAD51L3 using IHIC42 as the primary antibody. A negative control blot
was treated in exactly the same manner omitting the incubation with rRAD51L3.
Gel Filtration Chromatography--
200 µl of HeLa nuclear
extract was loaded onto a Superose 6 HR 10/30 (Amersham Pharmacia
Biotech) fast protein liquid chromatography column equilibrated with
buffer containing 25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM EDTA, 1 mM DTT.
0.5-ml fractions were collected and analyzed by Western blotting to
detect either RAD51L3 with IHIC42 or XRCC2 with IHIC48, as described above.
Purification of rRAD51L3--
RAD51L3 cDNA was
cloned into the pET30a expression vector that includes codons for an
N-terminal hexahistidine tag (His tag), an S-Tag, and thrombin
and enterokinase cleavage sites in its leader sequence. These
modifications added approximately 50 amino acids to the N terminus of
the RAD51L3 protein. The RAD51L3 protein was expressed in BL21( Purification of rXRCC2--
The XRCC2 cDNA was
cloned into pET30a, as described above. Following induction of XRCC2
expression in BL21( Generation of Anti-RAD51L3 and Anti-XRCC2
Antibodies--
Polyclonal anti-RAD51L3 (IHIC42) and anti-XRCC2
(IHIC48) antibodies were raised in rabbits. Using Western blotting,
IHIC42 recognized purified His-tagged rRAD51L3 (Fig.
2A, lane 2), and the
non-His-tagged RAD51L3-GST fusion protein (Fig. 2A,
lane 1), but not XRCC2-GST or human RAD51 protein (a gift
from Dr S. West, ICRF, London) (Fig. 2A, lanes 3 and
4). In WI-38/VA-13 whole cell extracts, a single band of
molecular mass approximately 35 kDa was detected by Western blotting
using IHIC42, consistent with the predicted molecular mass of native
RAD51L3 (Fig. 2B).
By using Western blotting, IHIC48 detected His-tagged rXRCC2 protein
and an XRCC2-GST fusion protein (Fig. 2C, lanes 1 and 2) but not rRAD51L3, human RAD51, or GST itself (Fig.
2C, lanes 3-5). There was considerable degradation of the
recombinant XRCC2 proteins leading to detection of multiple bands of
lower molecular mass. By using IHIC48, a band of molecular mass 31 kDa
was detected in whole cell extracts from WI-38/VA-13 cells, consistent
with the predicted size of native XRCC2 protein (Fig.
2D).
rRAD51L3 Is a DNA-stimulated ATPase--
All members of the
mammalian RAD51-like proteins contain "Walker box" motifs and are,
therefore, predicted to be adenine nucleotide-binding proteins (37).
rRAD51L3, like human RAD51 itself, was able to hydrolyze ATP.
Significant ATPase activity was seen in the absence of DNA, with a
small, but reproducible, stimulation of the ATPase activity by both
single- and double-stranded DNA (Fig.
3A). Single-stranded DNA was
the more efficient cofactor (Fig. 3, A and B).
The ATPase activity of rRAD51L3 was dependent upon the presence of a
divalent cation, with significant ATPase activity seen at
Mg2+ concentrations >0.1 µM (data not
shown). Mn2+ could partially substitute for
Mg2+ (Fig. 3C). In order to confirm that the
observed ATPase activity was directly associated with rRAD51L3,
individual eluted fractions from the heparin chromatography column were
dialyzed and assayed for ATPase activity as well as being subjected to
SDS-PAGE. There was a strong concordance between the level of ATPase
activity and the amount of rRAD51L3 protein in each fraction (Fig.
3D) indicating that the ability to hydrolyze ATP is an
intrinsic activity of the protein.
rRAD51L3 Preferentially Binds Single-stranded DNA--
Members of
the RAD51-like family are thought to play a role in homologous
recombination and DNA repair and would be predicted, therefore, to bind
DNA. By using oligonucleotide substrates (52 nucleotides in length),
rRAD51L3 was found to preferentially bind to single-stranded DNA
compared with blunt-ended double-stranded DNA (Fig.
4). The binding profiles for two
unrelated sequences of single-stranded oligonucleotides were identical
(data not shown), suggesting that RAD51L3 is unlikely to show strict
sequence preference for binding. DNA binding by RAD51L3 was not
dependent upon the presence of divalent metal ions or ATP (data not
shown).
RAD51L3 Physically Interacts with XRCC2 in Vivo--
The precise
functions of, and interactions between, the individual human RAD51-like
proteins are not known. In S. cerevisiae, Rad55p and Rad57p
form a heterodimer that stimulates Rad51-mediated strand
exchange activity (20). It is thought that some of the mammalian RAD51
homologs could, therefore, act in a similar manner. To address this, we
analyzed whether RAD51L3 and XRCC2 can physically interact. This was
studied initially using the yeast two-hybrid system. The complete open
reading frame of each gene was cloned into vectors carrying the LexA
DNA-binding domain (bait) or B42 activation domain (prey). As shown in
Fig. 5, RAD51L3 interacted strongly with
XRCC2 but showed no interaction with the negative control for
activation (Lamin).
Next, we asked whether RAD51L3 and XRCC2 form a complex in human cell
extracts. To do this, pull-down experiments were performed with
extracts from HeLa cells using XRCC2-GST bound to glutathione-agarose matrix. After washing the matrix, any bound complexes were boiled in
SDS loading buffer and separated by SDS-PAGE. Western blotting of the
fractions with anti-RAD51L3 antibodies (IHIC42) showed an
immunoreactive band of molecular mass 35 kDa, consistent with native
RAD51L3 being bound to XRCC2-GST on the matrix (Fig.
6A). This interaction was also
apparent in extracts from WI-38/VA-13 cells (data not shown).
Interestingly, the RAD51L3 was detected as a doublet, consistent with
possible phosphorylation of the protein. Reciprocal pull-down
experiments with RAD51L3-GST bound to glutathione-agarose were then
performed using extracts from HeLa cells. Western blotting of the
pulled down material with anti-XRCC2 antibodies (IHIC48) revealed a
band of molecular mass 31 kDa, consistent with native XRCC2 forming a
complex with RAD51L3-GST in human cell extracts (Fig. 6B).
Taken together, these data indicate that RAD51L3 and XRCC2 exist as (or
part of) a complex in human cells.
rRAD51L3 and XRCC2 Form a Complex in Vitro--
Next, we asked
whether the interaction between RAD51L3 and XRCC2 that we had detected
in human cell extracts was a direct one and therefore did not require
accessory factors. To do this, we used two independent methods to
ascertain whether the purified RAD51L3 and XRCC2 proteins can form a
complex in vitro. First, we performed pull-down experiments
using the recombinant RAD51L3-GST and XRCC2-GST fusion proteins. The
XRCC2-GST fusion protein was bound to glutathione-agarose and incubated
with recombinant His-tagged RAD51L3. The matrix was then washed, and
the bound material Western-blotted using anti-His tag antibodies. The
rRAD51L3 protein was retained on the matrix (Fig.
7A), indicating that XRCC2 and
RAD51L3 can bind directly to each other. In reciprocal pull-down
experiments, a direct interaction was demonstrated between RAD51L3-GST
and His-tagged XRCC2 (Fig. 7B). This interaction was
maintained at wash concentrations of up to 500 mM NaCl.
Far Western analysis with purified recombinant RAD51L3 and XRCC2-GST
was used as a second method to confirm a direct physical interaction
between the proteins. This procedure involved the immobilization of
XRCC2-GST on nitrocellulose membranes, denaturation, and refolding of
the protein on the membrane before incubation in buffer containing
His-tagged RAD51L3. Filters were then washed to remove unbound protein
before detection of the RAD51L3 protein by conventional Western
analysis. When probed with anti-RAD51L3 antibodies, an immunoreactive
band was detected at the position where XRCC2-GST migrates. Several
bands of higher mobility were also detected, consistent with
interactions between RAD51L3 and breakdown products from XRCC2-GST.
There was no evidence of interaction with GST alone, and no bands were
detected on a control blot treated in exactly the same manner apart
from incubation of the membrane in PBSA alone rather than with
His-tagged RAD51L3 protein (Fig. 7C).
Analysis of the Native Molecular Mass of RAD51L3 and XRCC2
Complexes in Human Cell Extracts--
The S. cerevisiae
Rad55 and Rad57 proteins form a heterodimer (20). We therefore
separated HeLa cell extracts by size-exclusion chromatography to
address whether the RAD51L3 and XRCC2 proteins elute in the same
fractions from the column, and whether they do so in a size range
consistent with the existence of a RAD51L3/XRCC2 heterodimer. The
eluted fractions were analyzed by SDS-PAGE and Western blotting with
either IHIC42 (anti-RAD51L3) or IHIC48 (anti-XRCC2) antibodies. RAD51L3
and XRCC2 were detected in the same eluted fractions at a molecular
mass (approximately 70 kDa), consistent with these proteins existing as
a heterodimer. Neither protein was detected in fractions where the
monomeric proteins would be expected to elute (Fig.
8).
We have expressed recombinant RAD51L3 cDNA in bacteria and
obtained protein at an estimated purity of >90% using nickel chelate and heparin chromatography. By using antibodies raised to this protein,
a single band of 35 kDa was detected in extracts from human cells,
consistent with the molecular mass of RAD51L3 predicted from the
nucleotide sequence (23, 24). RAD51L3 is a member of the RecA/RAD51
family, but the similarity of the protein to human RAD51 protein is low
and is confined primarily to the nucleotide-binding domains as well as
a few residues dispersed over the remainder of the protein (35).
However, the RAD51L3 protein is highly conserved from man to mouse (23,
24), suggesting that it plays an important role in mammals. It is
unlikely that this role is to act as a back-up to RAD51 in strand
transfer reactions, because disruption of the RAD51 gene in
mice leads to embryonic lethality (11, 12). Hence, it is clear that
none of the other RAD51-like proteins can replace the function of RAD51 itself.
An important feature of all RecA/RAD51-like proteins is the presence of
the Walker A and B boxes, which commonly indicate an ATPase function.
Accordingly, site-directed mutagenesis of the S. cerevisiae
and human RAD51 proteins at highly conserved residues in the Walker A
box leads to severe defects in function (7, 38). Similar experiments
with S. cerevisiae Rad55p and Rad57p, which form a
heterodimer and stimulate the action of Rad51p (20), have shown that
mutation of the Walker A box of Rad55p, but not of Rad57p, disables
function (13). This finding suggests that ATP hydrolysis may be
dispensable for some of the RecA/RAD51 family members. Here, we have
shown that purified RAD51L3 has significant ATPase activity in the
absence of DNA but that both single-stranded and double-stranded DNA
stimulate this activity. The rate of hydrolysis of ATP by RAD51L3 is
relatively slow but nevertheless similar to that of human RAD51. ATP
hydrolysis by human RAD51 is 2 orders of magnitude slower than the rate
shown by E. coli RecA, as noted previously (9, 39-41). It
may be that some modification of, or interaction between, the human
RAD51-like proteins is required before a high rate of ATP hydrolysis is
revealed. It remains to be tested whether interactions among the human
RAD51-like proteins will influence this activity of RAD51L3 protein.
An understanding of the DNA binding properties of members of the RAD51
family may help elucidate the roles that they play in the complex
process of homologous recombination. The E. coli RecA
protein binds preferentially to single-stranded DNA, but the RAD51
proteins from yeast and man bind single- and double-stranded DNA with a
similar affinity (9, 40, 42). These differences between prokaryotic and
eukaryotic DNA strand exchange proteins may reflect different
requirements for co-factors or accessory proteins to promote DNA
pairing and exchange. Indeed, in yeast, the Rad55/Rad57 heterodimer has
an enhanced affinity for single-stranded DNA, and there is experimental
support for a model in which these proteins facilitate the nucleation
of Rad51 onto DNA by displacing the single-stranded DNA-binding
protein, RPA (20). Our finding that single-stranded DNA is the
preferred substrate for binding by RAD51L3 is consistent with a similar
facilitating role for this protein in human cells.
As noted above, it is known that Rad55p and Rad57p interact to form a
heterodimer and that these proteins have some sequence similarities to
XRCC2 and RAD51L3, respectively. By using several different
experimental approaches, we have shown that the RAD51L3 protein and the
XRCC2 protein interact and that this interaction does not require
additional accessory factors. First, to assess in vivo the
interaction, we showed using the yeast two-hybrid system that XRCC2
interacts strongly with RAD51L3. Second, we showed that the RAD51L3 and
XRCC2 proteins physically interact in pull-down experiments, both using
purified recombinant proteins and human cell extracts. Finally, far
Western analysis with the purified recombinant proteins showed that
immobilized XRCC2 interacts with RAD51L3. These data argue strongly for
the existence of a direct interaction between the RAD51L3 and XRCC2
proteins in vivo. Our gel filtration analysis is consistent
with but does not prove that RAD51L3 and XRCC2 form a heterodimeric
complex in human cells. It is significant that no protein was detected
in the eluted fractions of a size expected for monomeric XRCC2 and RAD51L3.
Additional studies are required to assess the functional significance
of the XRCC2 and RAD51L3 interaction. Based on previous studies of the
Rad55 and Rad57 proteins, we anticipate that the proposed heterodimer
of XRCC2 and RAD51L3 will be required to promote the formation of RAD51
molecules on single-stranded DNA. The RAD51L3-XRCC2 complex
could influence the loading of Rad51 onto DNA in the presence of
single-stranded DNA-binding protein (20, 43) or help in the remodeling
of chromatin at damaged sites subject to homologous recombination
repair (44).
In addition to RAD51L3 and XRCC2, there are currently three other
members of the RAD51-like family in human cells as follows: XRCC3,
RAD51L1, and RAD51L2. In a recent review article, Thompson and Schild
(45) summarized their results of 2-hybrid analyses, which suggested
that multiple interactions may occur between RAD51-like proteins,
including an interaction between RAD51L3 and XRCC2. This raises the
possibility that, rather than acting as a heterodimer in a manner
analogous to yeast Rad55p and Rad57p, RAD51L3 and XRCC2 form part of a
complex containing multiple RAD51-like proteins and possibly RAD51
itself. However, given the yeast paradigm of a Rad55/Rad57 heterodimer
influencing Rad51-catalyzed reactions (20), together with our gel
filtration data, it perhaps seems more likely that the
RAD51L3/XRCC2 partnership is just one of several possible heterodimeric
complexes that participate in genetic recombination reactions in
mammalian cells.
The irs1 mutant hamster cell line defective in XRCC2 shows a
phenotype similar to that of yeast rad55/rad57 mutants in
being x-ray-sensitive and deficient in genetic recombination. However, a striking feature of XRCC2-deficient cells is their extreme
sensitivity to DNA cross-linking agents such as mitomycin C (29). This
raises the possibility that the RAD51L3-XRCC2 complex is particularly important in those recombination functions that are required for the
removal of DNA cross-links. This also suggests a possible scenario in
which different combinations of the multiple RAD51-like proteins in
human cells impart functionally different roles on RAD51.
In summary, we have purified the human RAD51L3 protein and partially
characterized its biochemical properties. We have also shown that
RAD51L3 forms a complex with XRCC2 protein in vitro and
in vivo. It is clear based on what we currently know about the roles of the RAD51-like proteins, such as from analysis of mutant
cell lines lacking XRCC2 or XRCC3, that the correct functioning of the
RAD51-like proteins is vital for the maintenance of genome stability in
mammalian cells. The goal for the future is to determine how XRCC2 and
RAD51L3 participate in recombination reactions in human cells.
We thank Alison Dunn and Rebecca Mason for
carrying out some of the initial experiments; Dr. S. West for RAD51
protein; Dr. C. Norbury for comments on the manuscript; members of the
ICRF Genome Stability Group for useful discussions; and Dr. D. Schild for communicating results prior to publication.
*
This work was supported by the Imperial Cancer Research Fund
(to J. P. B. and I. D. H.), the Medical Research Council, and the
European Commission (to K. G. S. and J. T.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
44-1865-222417; Fax: 44-1865-222431; E-mail:
hickson@icrf.icnet.uk.
Published, JBC Papers in Press, June 27, 2000, DOI 10.1074/jbc.M002075200
The abbreviations used are:
ORF, open reading
frame;
PMSF, phenylmethylsulfonyl fluoride;
DTT, dithiothreitol;
PAGE, polyacrylamide gel electrophoresis;
BSA, bovine serum albumin;
PBSA, phosphate buffered saline A;
GST, glutathione
S-transferase.
The RAD51 Family Member, RAD51L3, Is a DNA-stimulated ATPase That
Forms a Complex with XRCC2*
,
¶
Imperial Cancer Research Fund Laboratories,
Institute of Molecular Medicine, University of Oxford, John
Radcliffe Hospital, Oxford OX3 9DS and § Medical Research
Council Radiation and Genome Stability Unit, Harwell,
Oxfordshire OX11 ORD, United Kingdom
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-minimum Eagle's
medium supplemented with 10% fetal bovine serum, and HeLa S3 cells
were cultured in 2% RPMI plus 10% fetal bovine serum.
DE3) (New England
Biolabs) was transformed with either pJB3.1, pJB3.2, pJB1.1, or pJB1.2.
Individual colonies were picked and cultured overnight in LB media
containing selective antibiotic. Saturated cultures were inoculated
into LB at 1:100 dilution and incubated at 37 °C, with shaking,
until the culture reached an A600 of
0.6-0.8. Isopropyl-1-thio-
-D-galactopyranoside (Stratagene) was added to a final concentration of 0.4 mM,
and cultures were grown for a further 2 h before cooling on ice
for 15 min. Cells were harvested by centrifugation at 4 °C, and the pellet was resuspended in buffer containing 25 mM Tris-HCl,
pH 7.5, 250 mM NaCl (10 ml buffer per 400-ml culture) prior
to storage at
70 °C until required.
70 °C.
-32P]ATP. The
assay mixture (20 µl) contained 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 100 µg/ml BSA, 100 mM NaCl, 2.5 mM MgCl2 (or other
divalent metal ion) 25 µg/ml (76 µM nucleotides) DNA, 0.2 mM ATP, 50 nCi [
-32P]ATP (3000 Ci/mmol), and 1.0 µM rRAD51L3. After incubation at 37 °C for 2 h, the reaction was stopped by the addition of 10 µl of 0.5 M EDTA. 1 µl of each reaction was spotted
onto CEL 300 PEI/UV254 (Polygram) thin layer chromatography
plates, which were rinsed in 100% methanol before separation of
32Pi from [
-32P]ATP in buffer
containing 0.8 M LiCl, 0.8 M acetic acid.
Plates were exposed on PhosphorImager screens, and the percentage
release of 32Pi was quantified using ImageQuant
software (Molecular Dynamics).
-galactosidase reporter gene in a liquid culture assay using O-nitrophenyl
-D-galactopyranoside as substrate (36).
-glycerophosphate, 1 mM sodium orthovanadate, 5 mM sodium pyrophosphate, 1 mM glucose
1-phosphate, 10 nM microcystin, 0.1 mM
para-nitrophenyl phosphate, 1 mM PMSF, and
complete protease inhibitor mixture tablets (Roche Molecular
Biochemicals) according to manufacturer's instructions), on ice for 45 min. Nuclei were harvested at 5000 × g for 5 min. The
pellet was resuspended in 0.3 ml of TKM buffer (50 mM
Tris-HCl, pH 7.5, 5 mM MgCl2, 25 mM KCl, 1 mM DTT, supplemented with protease and phosphatase
inhibitors as described above) to which 0.6 ml of buffer D was added
(80 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.53 M NaCl, 1 mM DTT, supplemented with protease
and phosphatase inhibitors as above) before incubation on ice for 30 min. The nuclear extract was cleared by centrifugation at 14,000 rpm in
a microcentrifuge at 4 °C and used on the day of preparation.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
DE3)
bacteria, where the majority of overexpressed recombinant protein
formed insoluble inclusion bodies (Fig.
1A, lane P). Nevertheless, a
significant fraction of the recombinant protein was soluble (Fig.
1A, lane S), and this fraction was used as the source of
rRAD51L3 for purification by nickel chelate chromatography (Fig.
1A, lane Ni) and heparin chromatography (Fig. 1A, lane
Hep). The purified rRAD51L3 protein had an apparent molecular mass
of approximately 42 kDa, as determined by SDS-PAGE, and was recognized by a specific anti-His tag antibody (Fig. 1B). A chimeric
protein comprising RAD51L3 fused to GST (RAD51L3-GST) was also purified from E. coli for use in antibody validation and pull-down
experiments (see "Materials and Methods" and below).

View larger version (35K):
[in a new window]
Fig. 1.
Purification of rRAD51L3 protein.
A, Coomassie Blue-stained 12% SDS-polyacrylamide gel of
extracts of BL21(
DE3) cells transformed with pJB3.1 before
(U) and after (I) addition of
isopropyl-1-thio-
-D-galactopyranoside. Insoluble
inclusion bodies (P) formed greater than 50% of the induced
protein. The soluble lysate (S) was purified by nickel
chelate chromatography (Ni) and heparin affinity
chromatography (Hep). The position of recombinant RAD51L3
protein is indicated on the right. Molecular mass standards
are shown in lane M and their sizes in kDa are shown on the
left. B, Western blot, using an anti-histidine
tag antibody, of the purified rRAD51L3 protein eluted from the heparin
column. The position of the immunoreactive protein is indicated on the
right.
DE3), the vast majority of the recombinant
protein was found to be insoluble, with only trace amounts of protein
detectable in the soluble lysate. This soluble material, which was
insufficient for use in detailed enzymatic analyses, was purified by
nickel chelate chromatography. Confirmation that the purified protein
was XRCC2 was provided by Western blotting both with an anti-His tag
antibody (data not shown) and with an anti-XRCC2 antibody (IHIC48; see
below). A chimeric protein comprising XRCC2 fused to GST (XRCC2-GST)
was also purified following overexpression in E. coli (see
"Materials and Methods"). Analysis of this fusion protein is
described below.

View larger version (22K):
[in a new window]
Fig. 2.
Characterization of anti-RAD51L3 and
anti-XRCC2 antibodies. A, Western blot of recombinant
proteins using affinity purified IHIC42 (anti-RAD51L3) antibodies.
Lane 1, RAD51L3-GST; lane 2, His-tagged RAD51L3;
lane 3, XRCC2-GST; lane 4, human RAD51. The
positions of the RAD51L3-GST and His-tagged RAD51L3 proteins are
indicated on the right. B, Western blot of a
human WI-38/VA-13 cell extract for RAD51L3 using affinity purified
IHIC42 (anti-RAD51L3) antibodies. The position of the RAD51L3 protein
is indicated on the right. C, Western blot of
recombinant proteins using affinity purified IHIC48 (anti-XRCC2)
antibodies. Lane 1, His-tagged XRCC2; lane 2,
XRCC2-GST; lane 3, RAD51L3-GST; lane 4, human
RAD51; lane 5, GST. The positions of XRCC2-GST and
His-tagged XRCC2 are indicated on the right. D,
Western blot of a WI-38/VA-13 cell extract for XRCC2 using affinity
purified IHIC48 (anti-XRCC2) antibodies. The position of the XRCC2
protein is indicated on the right.

View larger version (29K):
[in a new window]
Fig. 3.
rRAD51L3 is a divalent
cation-dependent, DNA-stimulated ATPase. A,
time course for ATPase activity of rRAD51L3. RAD51L3 was incubated with
or without single- and double-stranded DNA (ssDNA and
dsDNA, respectively) co-factor as described under
"Materials and Methods." Aliquots were taken from each reaction mix
at the time points indicated, and the reaction was stopped by addition
of EDTA. B, DNA stimulation of the ATPase activity of
rRAD51L3. ATPase activity was quantified for heat-denatured rRAD51L3
(bar 1), and for native rRAD51L3 in the absence of DNA
(bar 2), or in the presence of native salmon sperm DNA
(bar 3), denatured salmon sperm DNA (bar 4),
supercoiled M13 plasmid DNA (bar 5), single-stranded
circular M13 DNA (bar 6), or a 52-mer oligonucleotide
(bar 7). Each value represents the mean of at least three
independent experiments. DNAs were present at a concentration of 25 µg/ml (76 µM nucleotides). C, the ATPase
activity of rRAD51L3 is metal ion-dependent. rRAD51L3 was
incubated with or without divalent metal ions (at 2.5 mM)
in the presence of 1 mM EDTA. Reactions contained
heat-denatured protein (Neg.) or native protein in the
absence of metal co-factor (None), or in the presence of
MgCl2 (Mg) or MnCl2 (Mn),
as indicated. Each value is the mean of three independent
determinations. Bars, S.D. D, fractions of
rRAD51L3 that eluted from the heparin affinity chromatography column
were analyzed by SDS-PAGE followed by Coomassie Blue staining
(upper panel). The position of rRAD51L3 protein is indicated
on the right. Lane M contained molecular mass
standards, with their sizes in kDa shown on the left. Each
fraction was also analyzed for ATPase activity (lower
panel). Fraction numbers are indicated above
each lane in the upper panel, and below each
point in the lower panel.

View larger version (34K):
[in a new window]
Fig. 4.
rRAD51L3 preferentially binds single-stranded
DNA. A, increasing concentrations of rRAD51L3 (0-50
nM, as indicated above the lanes) were incubated
with 5'-32P-labeled single- or double-stranded DNA
(ssDNA and dsDNA, respectively; 20 nM
nucleotides), as indicated below the lanes, before
separation by neutral 5% polyacrylamide gel electrophoresis.
Protein-DNA complexes and unbound DNA are indicated on the
right. B, quantification of the data from
A.

View larger version (15K):
[in a new window]
Fig. 5.
RAD51L3 interacts with XRCC2 by yeast
two-hybrid analysis. Values shown are the level of
-galactosidase (B-gal) activity for each combination of
"bait" and "prey," as indicated below the
bars. The level of
-galactosidase activity is an
indication of the strength of a protein-protein interaction. Fos + Jun is a positive control, and Lamin + RAD51L3 is a
negative control for activation. Values represent the mean of two
independent experiments.

View larger version (14K):
[in a new window]
Fig. 6.
RAD51L3 and XRCC2 interact in mammalian cell
extracts. Recombinant XRCC2-GST (A) or RAD51L3-GST
(B) fusion proteins were bound to glutathione-agarose matrix
and purified as described under "Materials and Methods." The bound
proteins were incubated with extracts from HeLa cells, the matrix was
washed, and bound proteins were subjected to SDS-PAGE followed by
Western blotting. A, Western blot for RAD51L3 using affinity
purified IHIC42. Lane 1, untreated nuclear extract (positive
control); lane 2, nuclear extract incubated with GST alone;
lane 3, nuclear extract incubated with XRCC2-GST. The
position of the RAD51L3 protein is indicated on the right.
B, Western blot for XRCC2 using affinity purified IHIC48.
Lane 1, untreated nuclear extract (positive control);
lane 2, nuclear extract incubated with GST; lane
3, nuclear extract incubated with RAD51L3-GST. The position of the
XRCC2 protein is indicated on the right.

View larger version (25K):
[in a new window]
Fig. 7.
rXRCC2 and rRAD51L3 interact directly.
Recombinant XRCC2-GST or RAD51L3-GST fusion proteins were bound to
glutathione-agarose matrix and purified as described under "Materials
and Methods." Purified proteins were either used in pull-down
experiments or far Western analysis. A, XRCC2-GST or GST
alone were incubated with His-tagged RAD51L3 before SDS-PAGE and
transfer to nitrocellulose membrane. Western blot for His-tagged
RAD51L3 using anti-His tag antibodies. Lane 1, rRAD51L3
positive control; lane 2, pull-down with GST; lane
3, pull-down with XRCC2-GST. The position of rRAD51L3 is shown on
the right. B, pull-down of rXRCC2 with either GST
alone (lane 1) or RAD51L3-GST (lane 2), as
detected by Western blotting with anti-His tag antibodies. The position
of the rXRCC2 protein is shown on the right. C,
far Western blotting analysis. Purified XRCC2-GST and GST were
subjected to SDS-PAGE (as indicated above the lanes) and
either stained with Coomassie Blue (left panel) or
transferred to nitrocellulose membranes (middle and
right panels). Proteins on the nitrocellulose membranes were
denatured and refolded before incubation either without (middle
panel; negative) or with His-tagged RAD51L3 (right panel;
positive). After washing, conventional Western blotting was
performed using affinity purified IHIC42 to detect the presence of
rRAD51L3, as indicated on the right.

View larger version (17K):
[in a new window]
Fig. 8.
RAD51L3 and XRCC2 from human cell extracts
co-elute on gel filtration chromatography. 200 µl of HeLa
nuclear extract was loaded onto a Superose-6 gel filtration column.
Individual fractions were collected, subjected to SDS-PAGE, and Western
blotted for either RAD51L3 (with IHIC42) or XRCC2 (with IHIC48). The
sizes of proteins in individual fractions were determined by running
molecular mass standards (
-amylase, 220 kDa; bovine serum albumin,
66 kDa; carbonic anhydrase, 29 kDa, as indicated above the
lanes). XRCC2 and RAD51L3 eluted in the same fractions at a native
molecular mass of approximately 70 kDa, consistent with the formation
of a heterodimer in human cells. The positions of the RAD51L3 and XRCC2
proteins are indicated on the right.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Paques, F.,
and Haber, J. E.
(1999)
Microbiol. Mol. Biol. Rev.
63,
349-404
2.
West, S. C.
(1992)
Annu. Rev. Biochem.
61,
603-640
3.
Aboussekhra, A.,
Chanet, R.,
Adjiri, A.,
and Fabre, F.
(1992)
Mol. Cell. Biol.
12,
3224-3234
4.
Basile, G.,
Aker, M.,
and Mortimer, R. K.
(1992)
Mol. Cell. Biol.
12,
3235-3246
5.
Muris, D. F.,
Vreeken, K.,
Carr, A. M.,
Broughton, B. C.,
Lehmann, A. R.,
Lohman, P. H.,
and Pastink, A.
(1993)
Nucleic Acids Res.
21,
4586-4591
6.
Ogawa, T., Yu, X.,
Shinohara, A.,
and Egelman, E. H.
(1993)
Science
259,
1896-1899
7.
Shinohara, A.,
Ogawa, H.,
and Ogawa, T.
(1992)
Cell
69,
457-470
8.
Shinohara, A.,
Ogawa, H.,
Matsuda, Y.,
Ushio, N.,
Ikeo, K.,
and Ogawa, T.
(1993)
Nat. Genet.
4,
239-243
9.
Sung, P.
(1994)
Science
265,
1241-1243
10.
Sung, P.,
and Robberson, D. L.
(1995)
Cell
82,
453-461
11.
Tsuzuki, T.,
Fujii, Y.,
Sakumi, K.,
Tominaga, Y.,
Nakao, K.,
Sekiguchi, M.,
Matsushiro, A.,
Yoshimura, Y.,
and Morita, T.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
6236-6240
12.
Lim, D. S.,
and Hasty, P.
(1996)
Mol. Cell. Biol.
16,
7133-7143
13.
Johnson, R. D.,
and Symington, L. S.
(1995)
Mol. Cell. Biol.
15,
4843-4850
14.
Hays, S. L.,
Firmenich, A. A.,
and Berg, P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
6925-6929
15.
Essers, J.,
Hendriks, R. W.,
Swagemakers, S. M.,
Troelstra, C.,
de Wit, J.,
Bootsma, D.,
Hoeijmakers, J. H.,
and Kanaar, R.
(1997)
Cell
89,
195-204
16.
Benson, F. E.,
Baumann, P.,
and West, S. C.
(1998)
Nature
391,
401-404
17.
Van Dyck, E.,
Hajibagheri, N. M.,
Stasiak, A.,
and West, S. C.
(1998)
J. Mol. Biol.
284,
1027-1038
18.
Van Dyck, E.,
Stasiak, A. Z.,
Stasiak, A.,
and West, S. C.
(1999)
Nature
398,
728-731
19.
Lovett, S. T.
(1994)
Gene (Amst.)
142,
103-106
20.
Sung, P.
(1997)
Genes Dev.
11,
1111-1121
21.
Albala, J. S.,
Thelen, M. P.,
Prange, C.,
Fan, W.,
Christensen, M.,
Thompson, L. H.,
and Lennon, G. G.
(1997)
Genomics
46,
476-479
22.
Dosanjh, M. K.,
Collins, D. W.,
Fan, W.,
Lennon, G. G.,
Albala, J. S.,
Shen, Z.,
and Schild, D.
(1998)
Nucleic Acids Res.
26,
1179-1184
23.
Cartwright, R.,
Dunn, A. M.,
Simpson, P. J.,
Tambini, C. E.,
and Thacker, J.
(1998)
Nucleic Acids Res.
26,
1653-1659
24.
Pittman, D. L.,
Weinberg, L. R.,
and Schimenti, J. C.
(1998)
Genomics
49,
103-111
25.
Kawabata, M.,
and Saeki, K.
(1998)
Biochim. Biophys. Acta
1398,
353-358
26.
Tambini, C. E.,
George, A. M.,
Rommens, J. M.,
Tsui, L. C.,
Scherer, S. W.,
and Thacker, J.
(1997)
Genomics
41,
84-92
27.
Cartwright, R.,
Tambini, C. E.,
Simpson, P. J.,
and Thacker, J.
(1998)
Nucleic Acids Res.
26,
3084-3089
28.
Liu, N.,
Lamerdin, J. E.,
Tebbs, R. S.,
Schild, D.,
Tucker, J. D.,
Shen, M. R.,
Brookman, K. W.,
Siciliano, M. J.,
Walter, C. A.,
Fan, W.,
Narayana, L. S.,
Zhou, Z. Q.,
Adamson, A. W.,
Sorensen, K. J.,
Chen, D. J.,
Jones, N. J.,
and Thompson, L. H.
(1998)
Mol. Cell
1,
783-793
29.
Jones, N. J.,
Cox, R.,
and Thacker, J.
(1987)
Mutat. Res.
183,
279-286
30.
Fuller, L. F.,
and Painter, R. B.
(1988)
Mutat. Res.
193,
109-121
31.
Tucker, J. D.,
Jones, N. J.,
Allen, N. A.,
Minkler, J. L.,
Thompson, L. H.,
and Carrano, A. V.
(1991)
Mutat. Res.
254,
143-152
32.
Tebbs, R. S.,
Zhao, Y.,
Tucker, J. D.,
Scheerer, J. B.,
Siciliano, M. J.,
Hwang, M.,
Liu, N.,
Legerski, R. J.,
and Thompson, L. H.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
6354-6358
33.
Johnson, R. D.,
Liu, N.,
and Jasin, M.
(1999)
Nature
401,
397-399
34.
Bishop, D. K.,
Ear, U.,
Bhattacharyya, A.,
Calderone, C.,
Beckett, M.,
Weichselbaum, R. R.,
and Shinohara, A.
(1998)
J. Biol. Chem.
273,
21482-21488
35.
Thacker, J.
(1999)
Trends Genet.
15,
166-168
36.
Golemis, E. A.,
Gyuris, J.,
and Brent, R.
(1996)
in
Current Protocols in Molecular Biology
(Ausubel, R.
, Brent, R.
, Kingston, D.
, Moore, J.
, Seidman, J.
, Smith, J.
, and Struhl, K., eds)
, pp. 13.6.2-13.6.3, Wiley Interscience, New York
37.
Thacker, J.
(1999)
Biochimie (Paris)
81,
77-85
38.
Donovan, J. W.,
Milne, G. T.,
and Weaver, D. T.
(1994)
Genes Dev.
8,
2552-2562
39.
Benson, F. E.,
Stasiak, A.,
and West, S. C.
(1994)
EMBO J.
13,
5764-5771
40.
Baumann, P.,
Benson, F. E.,
and West, S. C.
(1996)
Cell
87,
757-766
41.
Gupta, R. C.,
Bazemore, L. R.,
Golub, E. I.,
and Radding, C. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
463-468
42.
Zaitseva, E. M.,
Zaitsev, E. N.,
and Kowalczykowski, S. C.
(1999)
J. Biol. Chem.
274,
2907-2915
43.
Gasior, S. L.,
Wong, A. K.,
Kora, Y.,
Shinohara, A.,
and Bishop, D. K.
(1998)
Genes Dev.
12,
2208-2221
44.
Sugawara, N.,
Ivanov, E. L.,
Fishman-Lobell, J.,
Ray, B. L.,
Wu, X.,
and Haber, J. E.
(1995)
Nature
373,
84-86
45.
Thompson, L. H.,
and Schild, D.
(1999)
Biochimie (Paris)
81,
87-105
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H. W. Mankouri, H.-P. Ngo, and I. D. Hickson Shu Proteins Promote the Formation of Homologous Recombination Intermediates That Are Processed by Sgs1-Rmi1-Top3 Mol. Biol. Cell, October 1, 2007; 18(10): 4062 - 4073. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wiese, J. M. Hinz, R. S. Tebbs, P. B. Nham, S. S. Urbin, D. W. Collins, L. H. Thompson, and D. Schild Disparate requirements for the Walker A and B ATPase motifs of human RAD51D in homologous recombination. Nucleic Acids Res., January 1, 2006; 34(9): 2833 - 2843. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Gruver, K. A. Miller, C. Rajesh, P. G. Smiraldo, S. Kaliyaperumal, R. Balder, K. M. Stiles, J. S. Albala, and D. L. Pittman The ATPase motif in RAD51D is required for resistance to DNA interstrand crosslinking agents and interaction with RAD51C Mutagenesis, November 1, 2005; 20(6): 433 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yonetani, H. Hochegger, E. Sonoda, S. Shinya, H. Yoshikawa, S. Takeda, and M. Yamazoe Differential and collaborative actions of Rad51 paralog proteins in cellular response to DNA damage Nucleic Acids Res., August 10, 2005; 33(14): 4544 - 4552. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Smiraldo, A. M. Gruver, J. C. Osborn, and D. L. Pittman Extensive Chromosomal Instability in Rad51d-Deficient Mouse Cells Cancer Res., March 15, 2005; 65(6): 2089 - 2096. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Miller, J. M. Hinz, N.A. Yamada, L. H. Thompson, and J. S. Albala Nuclear localization of Rad51B is independent of Rad51C and BRCA2 Mutagenesis, January 1, 2005; 20(1): 57 - 63. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Yan, M Wang, W J Lemon, and M You Single nucleotide polymorphism (SNP) analysis of mouse quantitative trait loci for identification of candidate genes J. Med. Genet., September 1, 2004; 41(9): e111 - e111. [Full Text] [PDF] |
||||